Novo Nordisk, known for its successful diabetes and weight-loss medications, faced a significant drop in its stock price after failing to provide a convincing strategy for the future at its Capital Markets Day.
The company announced plans to introduce more than five potential blockbuster drugs by 2030, but analysts from Barclays and Jefferies expressed doubts about the effectiveness of these disclosures in boosting investor confidence.
Novo's CEO, Mike Doustdar, acknowledged the need to rebuild trust with investors, emphasizing that credibility must be established through consistent financial and scientific results.
The company is attempting to diversify its pipeline beyond diabetes and obesity, which had been its primary focus, but analysts remain concerned about its heavy reliance on obesity treatments as the exclusivity for semaglutide approaches its end.
Novo is also exploring acquisitions to fill gaps in its portfolio and is betting on a fragmented obesity market where patients may choose treatments based on various factors beyond just weight loss percentages. The company is developing several new drugs, including CagriSema and oral treatments, aiming to cater to different patient needs.
However, analysts from Citi remain cautious about the long-term pricing and competition in the obesity market, forecasting only mid-single-digit annual growth until 2030 and maintaining a neutral rating on the stock